Parkinson’s disease with early motor complications: predicting EQ-5D- 3L utilities from PDQ-39 data in the EARLYSTIM trial View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2020-03-02

AUTHORS

Mehdi Zahra, Isabelle Durand-Zaleski, Michal Górecki, Silke Walleser Autiero, Gillian Barnett, W. M. Michael Schüpbach

ABSTRACT

BackgroundA utility value is a health-related quality of life metric (HRQoL) metric used in a cost-effectiveness analysis. While utilities as outcomes in the treatment of advanced Parkinson’s disease (PD) with deep brain stimulation (DBS) are available, they do not currently exist for PD with early motor complications. The objectives of this study were to predict utilities from observed disease-specific HRQoL data using two mapping algorithms, and investigate their performance in terms of longitudinal changes within and between treatment groups, and distribution by PD severity.MethodsThis is a post hoc analysis of data from the EARLYSTIM trial of DBS compared with best medical therapy (BMT) in PD patients with early motor complications We used two published algorithms comprising ordinal and multinomial regression models to map EQ-5D-3L utilities from observed PD-specific 39 item Questionnaire (PDQ-39) scores in EARLYSTIM. Utilities were calculated using the predicted functioning levels of EQ-5D-3L dimensions and the established EQ-5D-3L UK tariffs. Statistical analyses (analysis of variance, two-tailed Student’s t-test) were used to test the change from baseline within groups and difference in change from baseline between groups in utilities. Boxplots were developed to investigate the distribution of predicted utilities by PD severity, measured using the Hoehn and Yahr scale.ResultsThe change from baseline in predicted mean utilities was statistically significant at all visits up to 24 months for the DBS group (p < 0.001) with both algorithms, and statistically significant at 12 months only (p = 0.04) for the BMT group with one algorithm. With both algorithms, the between-groups difference in change from baseline in predicted mean utilities favored DBS at all follow-up visits (p < 0.001). Based on the Hoehn and Yahr scale, predicted utilities deteriorated with increasing disease severity.ConclusionsAmong PD patients with early motor complications, utilities predicted by both mapping algorithms using PDQ-39 data demonstrated a statistically and clinically meaningful improvement with DBS compared with BMT. It was not possible to conclude if one algorithm was more responsive than other. In the absence of utilities collected directly from patients, mapping is an acceptable option permitting economic evaluations to be undertaken. More... »

PAGES

49

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12955-020-01299-y

DOI

http://dx.doi.org/10.1186/s12955-020-01299-y

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1125330400

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/32122369


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1109", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Neurosciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Algorithms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cost-Benefit Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Parkinson Disease", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Physical Functional Performance", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quality of Life", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Surveys and Questionnaires", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Medtronic International Trading Sarl, Route de Molliau 31, 1131, Tolochenaz, Tolochenaz, Switzerland", 
          "id": "http://www.grid.ac/institutes/grid.471158.e", 
          "name": [
            "Medtronic International Trading Sarl, Route de Molliau 31, 1131, Tolochenaz, Tolochenaz, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zahra", 
        "givenName": "Mehdi", 
        "id": "sg:person.014230321621.02", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014230321621.02"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Sant\u00e9 Publique H\u00f4pital Henri-Mondor, 51, avenue du Mal de Lattre de Tassigny, 94010, Cr\u00e9teil, France", 
          "id": "http://www.grid.ac/institutes/grid.457361.2", 
          "name": [
            "H\u00f4pital de l\u2019Hotel-Dieu, Ile de France, 1 Place du Parvis de Notre-Dame, 75004, Paris, France", 
            "Sant\u00e9 Publique H\u00f4pital Henri-Mondor, 51, avenue du Mal de Lattre de Tassigny, 94010, Cr\u00e9teil, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Durand-Zaleski", 
        "givenName": "Isabelle", 
        "id": "sg:person.01327533357.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01327533357.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Health Technology Assessment Consulting, Starowi\u015blna 17/3, 31-038, Krak\u00f3w, Poland", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Health Technology Assessment Consulting, Starowi\u015blna 17/3, 31-038, Krak\u00f3w, Poland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "G\u00f3recki", 
        "givenName": "Michal", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medtronic International Trading Sarl, Route de Molliau 31, 1131, Tolochenaz, Tolochenaz, Switzerland", 
          "id": "http://www.grid.ac/institutes/grid.471158.e", 
          "name": [
            "Medtronic International Trading Sarl, Route de Molliau 31, 1131, Tolochenaz, Tolochenaz, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Walleser Autiero", 
        "givenName": "Silke", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Gillian Barnett and Associates Limited, Claggan, Hornhead, Dunfanaghy, Letterkenny, Co. Donegal, Dunfanaghy, Ireland", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Gillian Barnett and Associates Limited, Claggan, Hornhead, Dunfanaghy, Letterkenny, Co. Donegal, Dunfanaghy, Ireland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Barnett", 
        "givenName": "Gillian", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Movement Disorders Center, Department of Neurology, Bern University Hospital and University of Bern, Freiburgstrasse 8, 3010, Bern, Switzerland", 
          "id": "http://www.grid.ac/institutes/grid.5734.5", 
          "name": [
            "Assistance Publique H\u00f4pitaux de Paris, Institut National de Sant\u00e9 et en Recherche M\u00e9dicale, Institut du Cerveau et de la Moelle Epini\u00e8re, Centre d\u2019Investigation Clinique 1422, D\u00e9partement de Neurologie, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, F-75013, Paris, France", 
            "Movement Disorders Center, Department of Neurology, Bern University Hospital and University of Bern, Freiburgstrasse 8, 3010, Bern, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sch\u00fcpbach", 
        "givenName": "W. M. Michael", 
        "id": "sg:person.0732250644.09", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0732250644.09"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s11136-012-0231-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037672713", 
          "https://doi.org/10.1007/s11136-012-0231-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1477-7525-11-35", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010278584", 
          "https://doi.org/10.1186/1477-7525-11-35"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf02260863", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013921031", 
          "https://doi.org/10.1007/bf02260863"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11136-008-9392-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001981620", 
          "https://doi.org/10.1007/s11136-008-9392-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10198-011-0351-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045435800", 
          "https://doi.org/10.1007/s10198-011-0351-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1477-7525-11-151", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051679514", 
          "https://doi.org/10.1186/1477-7525-11-151"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2020-03-02", 
    "datePublishedReg": "2020-03-02", 
    "description": "BackgroundA utility value is a health-related quality of life metric (HRQoL) metric used in a cost-effectiveness analysis. While utilities as outcomes in the treatment of advanced Parkinson\u2019s disease (PD) with deep brain stimulation (DBS) are available, they do not currently exist for PD with early motor complications. The objectives of this study were to predict utilities from observed disease-specific HRQoL data using two mapping algorithms, and investigate their performance in terms of longitudinal changes within and between treatment groups, and distribution by PD severity.MethodsThis is a post hoc analysis of data from the EARLYSTIM trial of DBS compared with best medical therapy (BMT) in PD patients with early motor complications We used two published algorithms comprising ordinal and multinomial regression models to map EQ-5D-3L utilities from observed PD-specific 39 item Questionnaire (PDQ-39) scores in EARLYSTIM. Utilities were calculated using the predicted functioning levels of EQ-5D-3L dimensions and the established EQ-5D-3L UK tariffs. Statistical analyses (analysis of variance, two-tailed Student\u2019s t-test) were used to test the change from baseline within groups and difference in change from baseline between groups in utilities. Boxplots were developed to investigate the distribution of predicted utilities by PD severity, measured using the Hoehn and Yahr scale.ResultsThe change from baseline in predicted mean utilities was statistically significant at all visits up to 24\u2009months for the DBS group (p\u00a0<\u20090.001) with both algorithms, and statistically significant at 12\u2009months only (p\u00a0=\u20090.04) for the BMT group with one algorithm. With both algorithms, the between-groups difference in change from baseline in predicted mean utilities favored DBS at all follow-up visits (p\u2009<\u20090.001). Based on the Hoehn and Yahr scale, predicted utilities deteriorated with increasing disease severity.ConclusionsAmong PD patients with early motor complications, utilities predicted by both mapping algorithms using PDQ-39 data demonstrated a statistically and clinically meaningful improvement with DBS compared with BMT. It was not possible to conclude if one algorithm was more responsive than other. In the absence of utilities collected directly from patients, mapping is an acceptable option permitting economic evaluations to be undertaken.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/s12955-020-01299-y", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1031326", 
        "issn": [
          "1477-7525"
        ], 
        "name": "Health and Quality of Life Outcomes", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "18"
      }
    ], 
    "keywords": [
      "early motor complications", 
      "deep brain stimulation", 
      "best medical therapy", 
      "motor complications", 
      "EQ-5D", 
      "Parkinson's disease", 
      "EARLYSTIM trial", 
      "PD patients", 
      "Yahr scale", 
      "PD severity", 
      "mean utility", 
      "advanced Parkinson's disease", 
      "health-related quality", 
      "between-group differences", 
      "cost-effectiveness analysis", 
      "BMT group", 
      "medical therapy", 
      "HRQoL data", 
      "DBS group", 
      "questionnaire scores", 
      "treatment groups", 
      "brain stimulation", 
      "complications", 
      "multinomial regression models", 
      "disease severity", 
      "meaningful improvements", 
      "longitudinal changes", 
      "patients", 
      "disease", 
      "acceptable option", 
      "absence of utility", 
      "baseline", 
      "severity", 
      "Hoehn", 
      "UK tariff", 
      "trials", 
      "visits", 
      "months", 
      "regression models", 
      "group", 
      "economic evaluation", 
      "MethodsThis", 
      "statistical analysis", 
      "therapy", 
      "utility values", 
      "analysis of data", 
      "stimulation", 
      "utility", 
      "outcomes", 
      "treatment", 
      "scores", 
      "differences", 
      "changes", 
      "data", 
      "options", 
      "levels", 
      "absence", 
      "evaluation", 
      "analysis", 
      "study", 
      "scale", 
      "improvement", 
      "objective", 
      "quality", 
      "values", 
      "distribution", 
      "model", 
      "boxplots", 
      "terms", 
      "mapping", 
      "dimensions", 
      "metrics", 
      "performance", 
      "mapping algorithm", 
      "algorithm", 
      "tariffs"
    ], 
    "name": "Parkinson\u2019s disease with early motor complications: predicting EQ-5D- 3L utilities from PDQ-39 data in the EARLYSTIM trial", 
    "pagination": "49", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1125330400"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12955-020-01299-y"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "32122369"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12955-020-01299-y", 
      "https://app.dimensions.ai/details/publication/pub.1125330400"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:47", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_855.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/s12955-020-01299-y"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12955-020-01299-y'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12955-020-01299-y'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12955-020-01299-y'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12955-020-01299-y'


 

This table displays all metadata directly associated to this object as RDF triples.

245 TRIPLES      21 PREDICATES      117 URIs      103 LITERALS      17 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12955-020-01299-y schema:about N39fcfcf5d4bf41c791a4a6ecec568bdb
2 N644b8f5e6c014df0922d9938c7731654
3 N77c784bf9fb34aaabb199e23ff16545b
4 N881c1c0dc7d94cc0aa4fb7877b9c5dbf
5 N99837e956ed04a50a266e8505cf11fd6
6 Nb655d3ad90de4d44a377f371083610f5
7 Nbe8312ab6eaa46ed86f4ef2bbf892f59
8 Nc4bba42e568b431197ac3920de3e6578
9 Nf1cc4a809eae4965a0bb96834003dc6d
10 Nf741ba4e2665491ca12b3327e2fddb38
11 anzsrc-for:11
12 anzsrc-for:1109
13 schema:author N486a96f5dfb946bb9a6307a613557b1e
14 schema:citation sg:pub.10.1007/bf02260863
15 sg:pub.10.1007/s10198-011-0351-x
16 sg:pub.10.1007/s11136-008-9392-8
17 sg:pub.10.1007/s11136-012-0231-6
18 sg:pub.10.1186/1477-7525-11-151
19 sg:pub.10.1186/1477-7525-11-35
20 schema:datePublished 2020-03-02
21 schema:datePublishedReg 2020-03-02
22 schema:description BackgroundA utility value is a health-related quality of life metric (HRQoL) metric used in a cost-effectiveness analysis. While utilities as outcomes in the treatment of advanced Parkinson’s disease (PD) with deep brain stimulation (DBS) are available, they do not currently exist for PD with early motor complications. The objectives of this study were to predict utilities from observed disease-specific HRQoL data using two mapping algorithms, and investigate their performance in terms of longitudinal changes within and between treatment groups, and distribution by PD severity.MethodsThis is a post hoc analysis of data from the EARLYSTIM trial of DBS compared with best medical therapy (BMT) in PD patients with early motor complications We used two published algorithms comprising ordinal and multinomial regression models to map EQ-5D-3L utilities from observed PD-specific 39 item Questionnaire (PDQ-39) scores in EARLYSTIM. Utilities were calculated using the predicted functioning levels of EQ-5D-3L dimensions and the established EQ-5D-3L UK tariffs. Statistical analyses (analysis of variance, two-tailed Student’s t-test) were used to test the change from baseline within groups and difference in change from baseline between groups in utilities. Boxplots were developed to investigate the distribution of predicted utilities by PD severity, measured using the Hoehn and Yahr scale.ResultsThe change from baseline in predicted mean utilities was statistically significant at all visits up to 24 months for the DBS group (p < 0.001) with both algorithms, and statistically significant at 12 months only (p = 0.04) for the BMT group with one algorithm. With both algorithms, the between-groups difference in change from baseline in predicted mean utilities favored DBS at all follow-up visits (p < 0.001). Based on the Hoehn and Yahr scale, predicted utilities deteriorated with increasing disease severity.ConclusionsAmong PD patients with early motor complications, utilities predicted by both mapping algorithms using PDQ-39 data demonstrated a statistically and clinically meaningful improvement with DBS compared with BMT. It was not possible to conclude if one algorithm was more responsive than other. In the absence of utilities collected directly from patients, mapping is an acceptable option permitting economic evaluations to be undertaken.
23 schema:genre article
24 schema:isAccessibleForFree true
25 schema:isPartOf N0f54ef06825544bface4971edba8dd9b
26 Nf6ecb184bcc44df690a7991a715b6cb7
27 sg:journal.1031326
28 schema:keywords BMT group
29 DBS group
30 EARLYSTIM trial
31 EQ-5D
32 HRQoL data
33 Hoehn
34 MethodsThis
35 PD patients
36 PD severity
37 Parkinson's disease
38 UK tariff
39 Yahr scale
40 absence
41 absence of utility
42 acceptable option
43 advanced Parkinson's disease
44 algorithm
45 analysis
46 analysis of data
47 baseline
48 best medical therapy
49 between-group differences
50 boxplots
51 brain stimulation
52 changes
53 complications
54 cost-effectiveness analysis
55 data
56 deep brain stimulation
57 differences
58 dimensions
59 disease
60 disease severity
61 distribution
62 early motor complications
63 economic evaluation
64 evaluation
65 group
66 health-related quality
67 improvement
68 levels
69 longitudinal changes
70 mapping
71 mapping algorithm
72 mean utility
73 meaningful improvements
74 medical therapy
75 metrics
76 model
77 months
78 motor complications
79 multinomial regression models
80 objective
81 options
82 outcomes
83 patients
84 performance
85 quality
86 questionnaire scores
87 regression models
88 scale
89 scores
90 severity
91 statistical analysis
92 stimulation
93 study
94 tariffs
95 terms
96 therapy
97 treatment
98 treatment groups
99 trials
100 utility
101 utility values
102 values
103 visits
104 schema:name Parkinson’s disease with early motor complications: predicting EQ-5D- 3L utilities from PDQ-39 data in the EARLYSTIM trial
105 schema:pagination 49
106 schema:productId N3fcd309e4cfd42da837cba4df1955dd4
107 N52c936880e754ea6a78f7fe70f17e357
108 Neb9d915d6dce49348e9dec2d3bf07cdf
109 schema:sameAs https://app.dimensions.ai/details/publication/pub.1125330400
110 https://doi.org/10.1186/s12955-020-01299-y
111 schema:sdDatePublished 2022-10-01T06:47
112 schema:sdLicense https://scigraph.springernature.com/explorer/license/
113 schema:sdPublisher Necd5c96db1784740bec5a25866553137
114 schema:url https://doi.org/10.1186/s12955-020-01299-y
115 sgo:license sg:explorer/license/
116 sgo:sdDataset articles
117 rdf:type schema:ScholarlyArticle
118 N0f54ef06825544bface4971edba8dd9b schema:volumeNumber 18
119 rdf:type schema:PublicationVolume
120 N39fcfcf5d4bf41c791a4a6ecec568bdb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Middle Aged
122 rdf:type schema:DefinedTerm
123 N3fcd309e4cfd42da837cba4df1955dd4 schema:name doi
124 schema:value 10.1186/s12955-020-01299-y
125 rdf:type schema:PropertyValue
126 N486a96f5dfb946bb9a6307a613557b1e rdf:first sg:person.014230321621.02
127 rdf:rest Nf9833165d3cd4a9d9c7b14d9b8e3ef4a
128 N52c936880e754ea6a78f7fe70f17e357 schema:name dimensions_id
129 schema:value pub.1125330400
130 rdf:type schema:PropertyValue
131 N644b8f5e6c014df0922d9938c7731654 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Physical Functional Performance
133 rdf:type schema:DefinedTerm
134 N6d71d0d82fcc4f3eb8299021229765cf schema:affiliation grid-institutes:grid.471158.e
135 schema:familyName Walleser Autiero
136 schema:givenName Silke
137 rdf:type schema:Person
138 N77c784bf9fb34aaabb199e23ff16545b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Male
140 rdf:type schema:DefinedTerm
141 N881c1c0dc7d94cc0aa4fb7877b9c5dbf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Quality of Life
143 rdf:type schema:DefinedTerm
144 N99837e956ed04a50a266e8505cf11fd6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Humans
146 rdf:type schema:DefinedTerm
147 Na750a059e03a492d8f31ede2538659d1 rdf:first N6d71d0d82fcc4f3eb8299021229765cf
148 rdf:rest Nb49ba31780d2428e9c749ef2c7040cc8
149 Nad20ff47e22447a5b09abc3ea85b38ac schema:affiliation grid-institutes:None
150 schema:familyName Górecki
151 schema:givenName Michal
152 rdf:type schema:Person
153 Naf518d4e4ec44eefb95735091bd419eb rdf:first Nad20ff47e22447a5b09abc3ea85b38ac
154 rdf:rest Na750a059e03a492d8f31ede2538659d1
155 Nb49ba31780d2428e9c749ef2c7040cc8 rdf:first Nebd86efd66264d45a67ff1b4504a8d50
156 rdf:rest Nd1d9dc67bf5e4d06aa9373ea68c5e642
157 Nb655d3ad90de4d44a377f371083610f5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Surveys and Questionnaires
159 rdf:type schema:DefinedTerm
160 Nbe8312ab6eaa46ed86f4ef2bbf892f59 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Female
162 rdf:type schema:DefinedTerm
163 Nc4bba42e568b431197ac3920de3e6578 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Algorithms
165 rdf:type schema:DefinedTerm
166 Nd1d9dc67bf5e4d06aa9373ea68c5e642 rdf:first sg:person.0732250644.09
167 rdf:rest rdf:nil
168 Neb9d915d6dce49348e9dec2d3bf07cdf schema:name pubmed_id
169 schema:value 32122369
170 rdf:type schema:PropertyValue
171 Nebd86efd66264d45a67ff1b4504a8d50 schema:affiliation grid-institutes:None
172 schema:familyName Barnett
173 schema:givenName Gillian
174 rdf:type schema:Person
175 Necd5c96db1784740bec5a25866553137 schema:name Springer Nature - SN SciGraph project
176 rdf:type schema:Organization
177 Nf1cc4a809eae4965a0bb96834003dc6d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
178 schema:name Parkinson Disease
179 rdf:type schema:DefinedTerm
180 Nf6ecb184bcc44df690a7991a715b6cb7 schema:issueNumber 1
181 rdf:type schema:PublicationIssue
182 Nf741ba4e2665491ca12b3327e2fddb38 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
183 schema:name Cost-Benefit Analysis
184 rdf:type schema:DefinedTerm
185 Nf9833165d3cd4a9d9c7b14d9b8e3ef4a rdf:first sg:person.01327533357.46
186 rdf:rest Naf518d4e4ec44eefb95735091bd419eb
187 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
188 schema:name Medical and Health Sciences
189 rdf:type schema:DefinedTerm
190 anzsrc-for:1109 schema:inDefinedTermSet anzsrc-for:
191 schema:name Neurosciences
192 rdf:type schema:DefinedTerm
193 sg:journal.1031326 schema:issn 1477-7525
194 schema:name Health and Quality of Life Outcomes
195 schema:publisher Springer Nature
196 rdf:type schema:Periodical
197 sg:person.01327533357.46 schema:affiliation grid-institutes:grid.457361.2
198 schema:familyName Durand-Zaleski
199 schema:givenName Isabelle
200 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01327533357.46
201 rdf:type schema:Person
202 sg:person.014230321621.02 schema:affiliation grid-institutes:grid.471158.e
203 schema:familyName Zahra
204 schema:givenName Mehdi
205 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014230321621.02
206 rdf:type schema:Person
207 sg:person.0732250644.09 schema:affiliation grid-institutes:grid.5734.5
208 schema:familyName Schüpbach
209 schema:givenName W. M. Michael
210 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0732250644.09
211 rdf:type schema:Person
212 sg:pub.10.1007/bf02260863 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013921031
213 https://doi.org/10.1007/bf02260863
214 rdf:type schema:CreativeWork
215 sg:pub.10.1007/s10198-011-0351-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1045435800
216 https://doi.org/10.1007/s10198-011-0351-x
217 rdf:type schema:CreativeWork
218 sg:pub.10.1007/s11136-008-9392-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001981620
219 https://doi.org/10.1007/s11136-008-9392-8
220 rdf:type schema:CreativeWork
221 sg:pub.10.1007/s11136-012-0231-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037672713
222 https://doi.org/10.1007/s11136-012-0231-6
223 rdf:type schema:CreativeWork
224 sg:pub.10.1186/1477-7525-11-151 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051679514
225 https://doi.org/10.1186/1477-7525-11-151
226 rdf:type schema:CreativeWork
227 sg:pub.10.1186/1477-7525-11-35 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010278584
228 https://doi.org/10.1186/1477-7525-11-35
229 rdf:type schema:CreativeWork
230 grid-institutes:None schema:alternateName Gillian Barnett and Associates Limited, Claggan, Hornhead, Dunfanaghy, Letterkenny, Co. Donegal, Dunfanaghy, Ireland
231 Health Technology Assessment Consulting, Starowiślna 17/3, 31-038, Kraków, Poland
232 schema:name Gillian Barnett and Associates Limited, Claggan, Hornhead, Dunfanaghy, Letterkenny, Co. Donegal, Dunfanaghy, Ireland
233 Health Technology Assessment Consulting, Starowiślna 17/3, 31-038, Kraków, Poland
234 rdf:type schema:Organization
235 grid-institutes:grid.457361.2 schema:alternateName Santé Publique Hôpital Henri-Mondor, 51, avenue du Mal de Lattre de Tassigny, 94010, Créteil, France
236 schema:name Hôpital de l’Hotel-Dieu, Ile de France, 1 Place du Parvis de Notre-Dame, 75004, Paris, France
237 Santé Publique Hôpital Henri-Mondor, 51, avenue du Mal de Lattre de Tassigny, 94010, Créteil, France
238 rdf:type schema:Organization
239 grid-institutes:grid.471158.e schema:alternateName Medtronic International Trading Sarl, Route de Molliau 31, 1131, Tolochenaz, Tolochenaz, Switzerland
240 schema:name Medtronic International Trading Sarl, Route de Molliau 31, 1131, Tolochenaz, Tolochenaz, Switzerland
241 rdf:type schema:Organization
242 grid-institutes:grid.5734.5 schema:alternateName Movement Disorders Center, Department of Neurology, Bern University Hospital and University of Bern, Freiburgstrasse 8, 3010, Bern, Switzerland
243 schema:name Assistance Publique Hôpitaux de Paris, Institut National de Santé et en Recherche Médicale, Institut du Cerveau et de la Moelle Epinière, Centre d’Investigation Clinique 1422, Département de Neurologie, Hôpital Pitié-Salpêtrière, F-75013, Paris, France
244 Movement Disorders Center, Department of Neurology, Bern University Hospital and University of Bern, Freiburgstrasse 8, 3010, Bern, Switzerland
245 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...